Urea
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Urea
Urea: Known uses and market status in Australia
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Urea, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use is a relation recorded in the knowledge graph, with no approval found.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| exanthem (disease) |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 4042R | Urederm | Cream 100 mg per g (10%), 100 g | Valid |
Safety Considerations
- Contraindications (knowledge graph, not label text): The TxGNN knowledge graph lists purulent otitis media, ear infection and otitis media as disease contraindication associations. These are not drawn from product label text and should be interpreted cautiously.
- Drug Interactions: 54 interactions were identified in the interaction database, all in the portion reviewed being of Moderate level. The main ones involve:
- Laxatives and bowel preparations (bisacodyl, picosulfuric acid, polyethylene glycol, lactulose, lactitol, magnesium hydroxide, magnesium citrate, sodium sulfate, castor oil, mineral oil, glycerin, phenolphthalein)
- SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin)
- Others (exenatide, sibutramine, iothalamic acid)
These listed interactions are likely relevant mainly to systemic use, and their significance for topical urea is unclear.
- Contact dermatitis: The literature notes that topical products can themselves cause allergic or irritant contact dermatitis.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications. The label text was not available in the compiled data.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.